Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity.
Qian
S
S
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Wang
Z
Z
Li
W
W
Chen
Z
Z
Zhang
H
H
Vickers
T
T
Fung
J J
JJ
Lu
L
L
D000818:Animals; D015703:Antigens, CD / Q000235:genetics*; D018122:B7-1 Antigen / Q000235:genetics*; D051940:B7-2 Antigen; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000235:genetics*; D051379:Mice; D008809:Mice, Inbred C3H; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology; D014184:Transplantation, Homologous
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497965:Cd86 protein, mouse; D008562:Membrane Glycoproteins; D020319:Oligodeoxyribonucleotides, Antisense; D012333:RNA, Messenger